Combination therapy or monotherapy for the depressed type of schizoaffective disorder

Abstract

Several studies have demonstrated the effectiveness of adjunctive antidepressant drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, however, monotherapy with atypical antipsychotics may be advantageous. We compared the efficacy and safety of risperidone monotherapy versus combination therapy of haloperidol with sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: risperidone: 3.75–3.29 mg/day, haloperidol: 5.35–4.15 mg/day, sertraline: 65.39–133.82 mg/day. Efficacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperidone patients showed statistically significant greater improvement than haloperidol-sertraline patients on efficacy measures including Positive and Negative Syndrome Scale and Clinical Global Impressions rating. A higher number of risperidone patients dropped out of the study early. Fewer adverse events and lesser need for concomitant medications occurred in patients on risperidone. The risperidone group showed better psychological, social and occupational functioning (Global Assessment of Functioning) and higher quality of life (Heinrich’s Quality of Life Scale). Risperidone has higher antipsychotic efficacy and tolerability compared with haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed type. Both treatments were comparable in terms of antidepressant efficacy.

Keywords:

• schizoaffective disorder
• depressed type
• risperidone
• haloperidol
• sertraline

Acknowledgements

Alojz Ritomský, PhD, Institute of Applied Psychology, Faculty of Social and Economic Sciences, Comenius University in Bratislava, Slovakia.

Disclosure

This manuscript was previously presented at the 20th ECNP Congress, October 13–17th, 2007, Vienna, Austria: Izáková L’. Monotherapy and combination therapy of schizoaffective disorder, depressive type. Abstract in: Eur Neuropsychopharm. 2007;17(Suppl 4):s. 414. Dr. Halaris is registered with the Speaker’s Bureau of Pfizer and Forest Laboratories and is a consultant for Pfizer.